ActivePhase 4ACTRN12610000704099

The Interactive Effect between Genetic Background of Heme Oxygenase-1 and Far Infrared Therapy on Arteriovenous (AV) Fistula Function in Hemodialysis Patients

The Effect of Far Infrared Therapy on the Access Blood Flow and Unassisted Patency of Arteriovenous Fistula in Hemodialysis Patients: Interaction with Length Polymorphisms of Heme Oxygenase-1 (HO-1) Gene

Sponsor

Taipei Veterans General Hospital

Enrollment

300 participants

Start Date

May 2, 2005

Study Type

Interventional

Conditions

Malfunction of AV fistula of hemodialysis (HD) patients

Summary

Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in hemodialysis (HD) patients. A shorter length polymorphism with Guanine Thymine repeat number [(GT)n] >30 in the heme oxygenase-1 (HO-1) gene was associated with better prognosis of arteriovenous fistula (AVF) in hemodialysis (HD) patients. Many methods of thermal therapy have been tried for improving Qa but with limited effects. This randomized trial is designed to evaluate (1) the effect of far infrared therapy (FIR) on access flow and patency of the native arteriovenous fistula (AVF) and (2) the interaction between HO-1 length polymorphism and FIR therapy on access flow (Qa) and patency of arteriovenous fistula (AVF) in HD patients.

Eligibility

Sex: Both males and femalesMin Age: 20 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study investigates whether far-infrared therapy can improve the function of the blood-vessel connection (AV fistula) used for dialysis, and whether genetics play a role. You must be aged 20 to 85, on dialysis for at least 6 months, and using a native AV fistula for at least 6 months. People with AV grafts, central vein narrowing, or a life expectancy under 12 months cannot participate.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

1. HD patients who are randomized into the treatment group will receive 40 minutes of far infrared therapy (FIR therapy) during hemodialysis three times per week for a year. 2. A Wide Spectrum (WS)

1. HD patients who are randomized into the treatment group will receive 40 minutes of far infrared therapy (FIR therapy) during hemodialysis three times per week for a year. 2. A Wide Spectrum (WS) TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. Its generated wavelengths range between 3 and 25 microm (a peak between 5 and 6 microm). The top radiator will be set at a height of 25 cm above the surface of the AV fistula with the treatment time set at 40 minutes during HD thrice a week for a year.

Locations(1)

Taiwan, Taiwan, Province Of China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000704099